Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aligos Therapeutics, Inc.

7.91
-0.0900-1.12%
Post-market: 7.910.00000.00%19:22 EDT
Volume:47.80K
Turnover:380.81K
Market Cap:48.37M
PE:-0.47
High:8.22
Open:7.45
Low:7.45
Close:8.00
Loading ...

Aligos Therapeutics Inc expected to post a loss of $2.36 a share - Earnings Preview

Reuters
·
Yesterday

Aligos Therapeutics Inc expected to post a loss of $2.36 a share - Earnings Preview

Reuters
·
01 Aug

Aligos Therapeutics to Announce 2nd Quarter 2025 Financial Results on August 6, 2025

GlobeNewswire
·
31 Jul

Aligos Therapeutics announces inducement grants under Nasdaq listing rule

TIPRANKS
·
11 Jul

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
11 Jul

Aligos Therapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
27 Jun

Press Release: Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC)

Dow Jones
·
18 Jun

BRIEF-Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule

Reuters
·
13 Jun

Aligos Therapeutics announces inducement grants under Nasdaq listing rule

TIPRANKS
·
13 Jun

Aligos Therapeutics to Present at the Jefferies Global Healthcare Conference

GlobeNewswire
·
29 May

Press Release: Aligos Therapeutics Appoints Laura Kavanaugh as Vice President, Head of Legal

Dow Jones
·
20 May

Aligos Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
06 May

Aligos Therapeutics Inc expected to post a loss of $2.80 a share - Earnings Preview

Reuters
·
02 May

UPS downgraded, ServiceNow upgraded: Wall Street's top analyst calls

The Fly
·
01 May

Nokia demonstrates the power of its flagship Wi-Fi 7 solution at Apex Legends Global Series esports gaming event

GlobeNewswire
·
30 Apr

Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025

GlobeNewswire
·
29 Apr

Aligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025

GlobeNewswire
·
24 Apr

Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation

Business Wire
·
14 Apr

Aligos Therapeutics Inc Files For Offering Of Up To 6.2 Million Common Shares By The Selling Securityholders - SEC Filing

Reuters
·
28 Mar

Aligos Therapeutics files to sell 6.25M shares of common stock for holders

TIPRANKS
·
28 Mar